Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 13.30B | 2.68B | 18.62B | 26.68B | 22.93B | 15.06B |
Gross Profit | 5.17B | 2.12B | 18.32B | 1.34B | 9.73B | 3.47B |
EBITDA | 704.00M | 3.55B | 1.47B | 11.06B | 11.08B | 1.34B |
Net Income | -337.00M | 2.23B | 1.10B | 8.16B | 8.24B | 642.00M |
Balance Sheet | ||||||
Total Assets | 399.16B | 389.40B | 379.27B | 360.32B | 416.21B | 410.15B |
Cash, Cash Equivalents and Short-Term Investments | 4.10B | 63.92B | 171.47B | 161.75B | 204.58B | 207.83B |
Total Debt | 9.46B | 12.39B | 11.87B | 15.33B | 15.68B | 11.25B |
Total Liabilities | 385.99B | 377.07B | 366.63B | 350.00B | 387.28B | 370.32B |
Stockholders Equity | 12.30B | 11.46B | 11.77B | 9.38B | 27.09B | 37.23B |
Cash Flow | ||||||
Free Cash Flow | 1.68B | 2.15B | 3.36B | 2.69B | 1.18B | 3.01B |
Operating Cash Flow | 1.68B | 2.15B | 3.36B | 2.69B | 2.46B | 3.33B |
Investing Cash Flow | -14.12B | -11.54B | -5.48B | -7.25B | -1.97B | -7.91B |
Financing Cash Flow | 12.08B | 9.58B | 2.11B | 4.67B | -809.00M | 4.67B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | 23.04B | 11.59 | 19.30% | 4.82% | 4.43% | 5.55% | |
76 Outperform | 12.57B | 46.48 | 2.53% | 5.25% | 4.72% | -67.85% | |
76 Outperform | 24.44B | 19.54 | 18.20% | 2.07% | 101.10% | 0.00% | |
73 Outperform | 31.69B | 12.38 | 10.44% | 2.72% | 11.66% | 67.88% | |
66 Neutral | 45.83B | 15.12 | 65.05% | 1.27% | 7.11% | 9.89% | |
52 Neutral | $17.03B | 27.46 | -2.89% | 3.00% | -18.21% | -116.73% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
On September 9, 2025, Corebridge Financial announced the appointment of Marc Costantini as its new President and CEO, effective December 1, 2025. Costantini, who brings extensive experience from Manulife and Munich Re, will succeed Kevin Hogan, who will transition to a special advisor role for six months. This leadership change is part of Corebridge’s strategic evolution as an independent company, aiming to leverage Costantini’s expertise in strategy, product innovation, and value creation to further its growth and market position.
The most recent analyst rating on (CRBG) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Corebridge Financial, Inc. stock, see the CRBG Stock Forecast page.
On August 6, 2025, Corebridge Financial, Inc. entered into an underwriting agreement with American International Group, Inc. and Morgan Stanley & Co. LLC for the sale of 30,000,000 shares of its common stock at $33.5113 per share. This agreement allows the selling stockholder to grant the underwriters a 30-day option to purchase an additional 4,500,000 shares to cover over-allotments, potentially impacting the company’s stock liquidity and market presence.
The most recent analyst rating on (CRBG) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Corebridge Financial, Inc. stock, see the CRBG Stock Forecast page.